Abbreviations {#nomen0010}
=============

A.U

:   arbitrary units

AB

:   alcian blue

CM

:   conditioned medium

DMEM

:   Dulbecco modified Eagle medium

DPP-IV

:   dipeptidyl peptidase-IV

EECs

:   enteroendocrine cells

FBS

:   fetal bovine serum

FXR

:   farnesoid X receptor

GLP

:   glucagon-like peptide

H&E

:   hematoxylin and eosin

IELs

:   intraepithelial lymphocytes

IR

:   insulin receptor

IRS1

:   insulin receptor substrate 1

LPS

:   lipopolysaccharide

MCD

:   methionine and choline-deficient

NAFLD

:   non-alcoholic fatty liver disease

NASH

:   non-alcoholic steatohepatitis

PAS

:   periodic acid-Schiff

PICRUSt

:   Phylogenetic Investigation of Communities by Reconstruction of Unobserved States

PTP1B

:   protein tyrosine phosphatase 1 B

STC-1

:   intestinal secretin tumor-1

UHPLC

:   ultra-high performance liquid chromatography

ZO-1

:   zonula occludens-1

1. Introduction {#sec1}
===============

Non-alcoholic fatty liver disease (NAFLD) is the most frequent chronic hepatic disease in Western countries and is considered the hepatic manifestation of metabolic syndrome \[[@bib1]\]. NAFLD is characterized by the accumulation of different lipid species within the hepatocyte that, together with pro-inflammatory cytokines, are the major triggers of disease progression. Moreover, 10%--40% of patients with NAFLD can progress to more advanced stages when adaptive mechanisms that protect hepatocytes from fatty acid-mediated lipotoxicity become overwhelmed, resulting in the development of non-alcoholic steatohepatitis (NASH), in which hepatic tissue presents a robust pro-inflammatory component. If unresolved, the disease can reach more severe stages such as fibrosis, cirrhosis (15%--25%), or even hepatocellular carcinoma (7%) \[[@bib2]\]. NAFLD represents an important public health problem due the increased incidence of metabolic syndrome worldwide \[[@bib3]\]. Therefore, elucidation of the molecular mechanisms and associated factors involved in the establishment and progression of NAFLD is crucially needed to identify new targets and implement efficient therapies.

Currently, the association between the gut--liver axis and gut microbiota is acquiring a major impact in the research on liver diseases as it is indispensable for metabolic regulation, gut hormone release, and immune responses \[[@bib4]\]. A recent study of the metagenomic signature of hepatic steatosis in a cohort of non-diabetic women with morbid obesity has provided evidences on the association of hepatic steatosis with low microbial gene richness and dysregulation of aromatic and branched-chain amino acid metabolism \[[@bib5]\]. The progression of NAFLD to more severe stages also correlates with alterations in the intestinal microbiota by affecting digestion, immune responses, and production of gut hormones \[[@bib6]\]. Moreover, Loomba and co-workers \[[@bib7]\] in a cohort of biopsy-proven patients with NAFLD with several degrees of fibrosis have described a panel of gut microbiome biomarkers that can be used as a non-invasive test to accurately diagnose advanced fibrosis in patients with NASH. In addition, interventional studies with probiotics such as VSL\#3 and *Lactobacillus casei Shirota* and prebiotics such as fermentable dietary fructo-oligosaccharides suggest that their administration may improve NAFLD \[[@bib8], [@bib9], [@bib10]\].

In the context of metabolic homeostasis, it is worth mentioning that the intestine has a complex network of specialized cells known as enteroendocrine cells (EECs) that secrete hormones to maintain energy balance by regulating food intake, digestion, absorption, satiation, storage, and disposal of digested nutrients \[[@bib11]\]. Recent interest has emerged on the interaction of EECs with the immune system and, in this regard, plasma glucagon-like peptide (GLP)-1 levels rapidly increase on lipopolysaccharide (LPS) administration in mice via a toll-like receptor 4 (TLR4)-dependent mechanism \[[@bib12],[@bib13]\]. Therefore, GLP-1 could be released to exert an anti-inflammatory effect in response to a pro-inflammatory situation such as an increase in endotoxin or cytokines \[[@bib14]\].

Insulin resistance plays an important role in the development of NAFLD \[[@bib15]\]. Protein tyrosine phosphatase 1 B (PTP1B) is a phosphatase ubiquitously expressed that acts as a negative regulator of insulin action since it dephosphorylates tyrosine residues, primarily insulin receptor (IR) and insulin receptor substrate 1 (IRS1), in critical nodes of the insulin signaling cascade \[[@bib16], [@bib17], [@bib18]\]. Global PTP1B-deficient mice are resistant to diet-induced obesity \[[@bib19]\] and do not show metabolic alterations during aging such as fat mass accretion, hepatic steatosis, and hyperinsulinemia \[[@bib20]\]. Of relevance, PTP1B is also an immune modulator as it controls cytokine-mediated signaling by dephosphorylating JAK2 in the JAK-STAT pathway and the non-receptor tyrosine protein kinase 2 (TYK2), among others \[[@bib21], [@bib22], [@bib23]\]. In this regard, a previous study in our laboratory has evidenced an exacerbated response of PTP1B-deficient *versus* wild-type (WT) macrophages to pro-inflammatory stimuli with increased expression of M1 polarization markers \[[@bib24]\]. Furthermore, when challenged with a methionine and choline-deficient (MCD) diet, PTP1B knockout (KO) mice developed hepatic inflammation and NASH more rapidly than their WT counterparts. By contrast, when mice with established MCD-induced NASH were switched to a chow diet, those lacking PTP1B manifested an accelerated recovery due, at least in part, to hepatic oval cells proliferation \[[@bib25]\]. Taking all these data into account, we hypothesized that in the context of the inflammatory environment associated with NASH, PTP1B could modulate specific cellular mechanisms in the gut. Based on that, in this work we have explored gut inflammation during NASH and, particularly, the role of PTP1B in the gut barrier function associated with this pro-inflammatory context. To achieve this goal, and considering that PTP1B-deficient mice are protected against obesity-induced NAFLD, an MCD dietary challenge was used as a preclinical model of non-obese NASH \[[@bib26]\]. Although the MCD diet has been criticized because it causes body weight loss \[[@bib27]\], it rapidly induces a NASH signature correlative to that found in humans and, importantly, it induces inflammation in the gut \[[@bib28]\]. Our results have provided experimental evidences of a role of PTP1B in the gut during NASH, particularly with respect to gut microbiota, inflammation, and gut barrier integrity.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

In this study we used WT mice (C57BL/6 J) or *Ptpn1* heterozygous mice of both sexes, maintained on a mixed genetic background (C57BL/6 J × 129 sv), that were intercrossed to yield the three genotypes of mice (WT, heterozygous, and KO), as described previously \[[@bib20]\]. The mice were housed at the animal facilities of the Alberto Sols Biomedical Research Institute (CSIC-UAM, Madrid). To induce experimental NASH, 12- to 16-week-old PTP1B WT or *Ptpn1* KO (PTP1B KO) male mice were fed a MCD diet (TD-90262 Harlan-Tecklad, Indianapolis, IN, USA) up to 4 weeks. The control animals were fed a chow diet during this period. Body weight was monitored weekly. Mice were maintained in 12-hour light/dark, temperature-controlled (22 °C), and humidity-controlled rooms. All animal experimentation was conducted in accordance with Spanish and European legislation and UK animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039), and approved by the CSIC and Comunidad de Madrid Animal Care and Use Committees and the University of Cambridge Animal Welfare and Ethical Review Body.

2.2. Microbiome analysis {#sec2.2}
------------------------

Fecal content was freshly collected individually, weighed, and frozen at −80 °C until use. Genomic DNA was extracted using the FastDNA ® SPIN Kit for Soil (MP Biomedicals, CA, USA) following the manufacturer\'s instructions. The homogenization step was conducted in a FastPrep® Instrument (MP Biomedicals, USA) for 10 s at a speed setting of 5.5. DNA quantity and quality were measured using the NanoVue plus system (GE Healthcare Life Science, UK). All samples were diluted to a 100 ng/μL final concentration. Polymerase chain reaction (PCR) amplification of V3--V4 hypervariable regions of 16 S rRNA genes was performed using the following primers \[[@bib29]\]: 16SV3V4-Fw: ACACTGACGACATGGTTCTACACCTACGGGNGGCWGCAG and 16SV3V4-Rv: TACGGTAGCAGAGACTTGGTCTGACTACHVGGGTATCTAATCC. Sequencing was performed in the Genomic Unit at Parque Cientifico de Madrid (Spain) using the Illumina-Myseq system (Illumina, San Diego, CA) following the manufacturer\'s guidelines. An average of 160,000 readings per sample was obtained. Paired reads were joined using the PandaSeq Assembler. Only sequences ranging from 300 to 460 bp were considered. Operational taxonomic units (OTUs) were determined using the GreenGenes 13_5 reference sequences database. The Miseq sequences derived from the 16 S profiling were deposited in the European Nucleotide Archive and are available under the following accession number: PRJEB13752. Community diversity (α-diversity) was calculated using Quantitative Insights into Microbial Ecology (QIIME) with the Shannon index \[[@bib30]\]. QIIME was used to determine β-diversity by calculating the weighted and unweighted UniFrac distances \[[@bib31]\]. EMPEROR was employed to visualize a UniFrac PCoA biplot. 16 S rDNA data were analyzed by the software Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) to predict metagenomics functional content by using OTUs picked against Greengenes 13_5 and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases \[[@bib32]\].

2.3. FITC-dextran assay {#sec2.3}
-----------------------

A 60 mg per 100 g of body weight dose of fluorescein isothiocyanate (FITC)-Dextran (FITC-Dextran 4 kDa, Sigma Aldrich, USA) dissolved in sterile phosphate-buffered saline (PBS) was administered by oral gavage to PTP1B WT or PTP1B KO mice fed a MCD or chow diet. Blood samples were collected by submandibular bleeding after 4 h in special tubes for small volumes (SST™ Tubes BD Microtainer®). Serum was obtained after centrifugation at 3000 × g for 10 min at 4 °C, and fluorescence was measured at 485 nm (excitation) and 535 nm (emission) with the Fluorometer Biotek Synergy™ HT and analyzed with GEN 5™1.07 software. The FITC-Dextran concentrations were determined from a standard curve with serial dilutions of FITC-Dextran.

2.4. Measurement of circulating endotoxemia {#sec2.4}
-------------------------------------------

Blood was collected from PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks in glass tubes (TU04-127-250, Labbox, Barcelona, Spain). Serum samples were obtained after centrifugation at 3000 × g for 10 min and stored in glass vials (SV02-A20-100, Labbox, Barcelona, Spain) at −80 °C. Endotoxemia was determined by enzyme-linked immunosorbent assay (ELISA) with the Mouse Endotoxin (ET) ELISA Kit (QAYEE-BIO, China) following the manufacturer\'s instructions.

2.5. Colon tissue collection {#sec2.5}
----------------------------

The colon was removed, and its length and weight were measured. Once the luminal content was removed with PBS, 5-mm pieces were cut and fixed with Methacarn (60% methanol, 30% chloroform, and 10% acetic acid) for 24 h at 4 °C. After fixation, pieces were washed with PBS and paraffin-embedded as follows: dehydration: 3 × 1 h in 96% ethanol, 3 × 1 h in 100% ethanol, 3 × 1 h in isoparaffin; paraffinization: 3 × 2 h in paraffin in a 60 °C oven. Next, 5-μm-thick sections were obtained using a standard microtome (Microm) and mounted on silanized glass slides for staining.

2.6. Evaluation of colon mucosal integrity and crypt length {#sec2.6}
-----------------------------------------------------------

Once the samples were dewaxed and rehydrated, they were stained using the hematoxylin and eosin (H&E) technique as follows. Sections were immersed in filtered Harris Hematoxylin for 10 s, washed with tap water, immersed in eosin for 30 s, washed with tap water, and dehydrated in ascending alcohol solutions. Colon sections stained with H&E were evaluated by a single blinded pathologist looking for inflammatory infiltrates, epithelial changes such as hyperplasia, and altered crypt architecture. Colon images were taken with the slide scanner Axio Scan. Z1 (Zeiss, Germany). Crypt lengths (μm) were quantified in periodic acid-Schiff (PAS)-stained sections using the Fiji version of Image J software (<http://fiji.sc/Fiji>). Measurements were taken from at least 27 full-length crypts obtained from five different longitudinal sections (per mouse).

2.7. Analysis of colonic neutral and acid mucins {#sec2.7}
------------------------------------------------

Colonic mucins were determined following the PAS histochemical technique \[[@bib33]\] and alcian blue (AB) stains. Briefly, 5-μm sections were stained with AB for 15 min and washed with distilled water. Then, samples were treated with periodic acid (1%) for 5 min, washed with distilled water, treated with the Schiff reagent for 5 min, and washed again. Finally, nuclei were counterstained using Harris Hematoxylin for 2 min. The neutral mucins were stained in magenta, whereas the acid mucins were stained in blue. The Fiji version of ImageJ software was used to obtain neutral and acid mucin scores. Results, expressed in arbitrary units (A.U.), correspond to the optical intensity × surface of magenta and blue staining after spectral separation of both colors. Only intact crypts were quantified.

2.8. Measurement of colon edema {#sec2.8}
-------------------------------

The colon was sectioned in 1-cm pieces after its extraction. Sections were homogenously distributed over a filter and placed into the moisture analyzer MB120 (Ohaus, Switzerland). Moisture was determined from the weight loss of the sample dried by heating. The temperature profile selected was a standard drying at 140 °C. The drying was considered finished when no changes at the level of milligrams were produced for at least 180 s.

2.9. ZO-1 immunofluorescence {#sec2.9}
----------------------------

Five-micron colonic paraffin sections were dewaxed and rehydrated. Antigen retrieval was performed with 10 mM sodium citrate and 0.05% Tween-20 (pH 7.4) for 10 min at 100 °C. H~2~O~2~ (3%): methanol (1:1) was used to block endogenous peroxidase for 30 min. Blocking was performed with 5% bovine serum albumin (BSA) and 4% goat serum for 1 h at room temperature. Samples were incubated with 1:50 anti-zonula occludens-1 (ZO-1) antibody (ZO-1-1A12, Invitrogen) overnight at 4 °C. Incubation with secondary antibody Rhodamine Red-X (Jackson ImmunoResearch) and 4,6-diamino-2-phenylindole (DAPI; Sigma) was performed for 1 h at room temperature. Images were taken using the confocal microscope LSM710 (Zeiss, Oberkochen, Germany).

2.10. RNA isolation and quantitative real-time PCR analysis {#sec2.10}
-----------------------------------------------------------

The colon was immediately frozen in liquid nitrogen after its collection. Colon homogenization was performed using the Tissue Lyser LT (Qiagen, Hilden, Germany) for 4 min, 30 s in TRIzol® Reagent (Invitrogen, USA) followed by a chloroform and isopropanol extraction. We used the Turbo DNA-free™ kit (Invitrogen by ThermoFisher Scientific, USA) for DNA digestion and the iScript™ cDNA Synthesis Kit (BioRad, USA) to conduct the cDNA synthesis following the manufacturer\'s instructions. SYBER Green-based quantitative PCR was performed with Kapa SYBR® FAST (Kapa Biosystems, Roche, Switzerland). Quantification was done through delta Ct analysis.

2.11. GLP-1 measurement in plasma {#sec2.11}
---------------------------------

Overnight fasted mice were administered a dose of 6 g/kg glucose by oral gavage. After 10 min, blood samples were collected in cold ethylenediamine tetraacetic acid (EDTA) tubes (BD Vacutainer® spray-coated K2EDTA Tubes, BD, USA) containing dipeptidyl peptidase-IV (DPP-IV) inhibitor (DPP4, EMD Millipore, USA) at a final concentration of 25 μM. Blood samples were centrifuged at 3000 × g for 10 min at 4 °C. After collection of plasma samples, DPP-IV inhibitor was added up to a final concentration of 50 μM, and samples were then immediately frozen and stored at −80 °C. GLP-1 was determined using a total GLP-1 assay kit (MesoScale Discovery, USA).

2.12. Acute pro-inflammatory systemic model in mice {#sec2.12}
---------------------------------------------------

C57BL/6 J male mice were treated with a single intraperitoneal injection of LPS (2 mg/kg body weight). For GLP-1 measurement, plasma samples were collected 16 h after the LPS challenge following 4 h of fasting and administration of 6 g/kg glucose by oral gavage as previously described.

2.13. Plasma bile acids profiling {#sec2.13}
---------------------------------

After protein precipitation with 3 volumes of cold (−20 °C) acetonitrile, samples were centrifuged. The separated supernatant solvent was evaporated, and the residue was resuspended in methanol:water (same volume as plasma). The plasma bile acids content was determined by ultra-high performance liquid chromatography (UHPLC) using a 1290 Infinity II LC System connected to a 6460 Triple Quadrupole MS as the instrument detector, both from Agilent Technologies (Santa Clara, CA, USA). A Zorbax Eclipse Plus C8 2.1 × 150-mm 1.8-μm column (Agilent Technologies, Spain) and an optimized gradient with acetonitrile, methanol, and ammonium acetate (pH 4) were used for bile acid separation. The analysis was performed at the Center for Metabolomics and Bioanalysis (CEMBIO), Universidad CEU-San Pablo, Madrid, Spain, based on previously described methodology \[[@bib34]\] with slight modifications. Commercial standards from Sigma (St. Louis, MO, USA) were used for all the bile acid measurements. D4-deoxycholic acid was used as the internal standard (IS). Calibration curves were prepared with seven concentrations of each standard.

2.14. Conditioned media production in macrophages {#sec2.14}
-------------------------------------------------

Raw 246.7 murine macrophages cell line was used to obtain a pro-inflammatory macrophage-conditioned medium (mCM) for performing *in vitro* experiments. Macrophages were cultured in T75 flasks (BD Falcon™, USA) in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics (1% P/S; 100 U/mL penicillin, 100 μg/mL streptomycin) at 37 °C in a humidified atmosphere with 5% CO~2~. Medium was collected after the treatment of confluent macrophages with 100 ng/mL LPS (InvivoGen, California, USA) with or without 20 μM of PTP1B inhibitor (Ref. 539,741, Sigma--Aldrich) in Dulbecco modified Eagle medium (DMEM) supplemented with 2% FBS and 1% P/S for 16 h \[referred to as mCM-lipopolysaccharide (mCM-LPS)\]. As a control, mCM was collected from unstimulated macrophages maintained for the same time period in DMEM-2% FBS-1% P/S (referred to as mCM-C).

Peritoneal macrophages were plated at 10-12 × 10^6^ cells per dish and maintained in RPMI medium supplemented with 10% FBS and 1% P/S for 2 h. Then, the medium was changed to DMEM supplemented with 2% FBS and 1% P/S for 24 h. To obtain the CM, macrophages were treated or not with 150 ng/mL LPS for 18 h in DMEM-2% FBS-1% P/S (referred as pCM-LPS or pCM-C, respectively).

2.15. Culture of STC-1 enteroencocrine cells {#sec2.15}
--------------------------------------------

Confluent STC-1 (intestinal secretin tumor-1) cells were maintained in DMEM supplemented with 10% FBS and 1% P/S. For experiments, STC-1 cells were treated with mCM-LPS or mCM-C for several time-periods to analyze pro-inflammatory signaling cascades or for 16 h prior to stimulation with 1 nM insulin (Sigma--Aldrich, Missouri, USA) for 10 min to analyze insulin signaling. To inhibit PTP1B enzymatic activity, STC-1 cells were pretreated with the PTP1B inhibitor (20 μM) for 2 h prior to the treatment of the cells with either mCM. We also supplemented the mCM with the same concentration of the inhibitor thorough the experiment. Then, the cells were washed twice with PBS and collected for further analysis.

2.16. Analysis of protein expression by western blot {#sec2.16}
----------------------------------------------------

STC-1 cells were homogenized in lysis buffer containing 10 mM Tris--HCl, 1 mM MgCl~2~, 1 mM Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 10% glycerol, 0.5% 3-\[(3-Cholamidopropyl)dimethylammonio\]-1-propanesulfonate hydrate (CHAPS), 1 mM β-mercaptoethanol, 0.1 mM phenymethylsulfonyl fluoride (PMSF), and 5 mg/mL of a protease and phosphatase inhibitor cocktail (Sigma--Aldrich, USA), pH 7.5. The extracts were centrifuged for 20 min at 13,000 × g at 4 °C, and supernatants were stored at −20 °C. Protein levels were determined using the Bradford dye method (Bio-Rad, USA). Protein extracts were boiled at 95 °C for 5 min in loading buffer \[250 mM Tris--HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol, and 2% β-mercaptoethanol\] and subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred onto nylon membranes (Immobilon P, Millipore, USA). Blots were incubated for 2 h at room temperature or overnight at 4 °C with primary antibodies against phospho-AKT Ser308, phospho-AKT Ser473, phospho-IR, phospho-JNK and phospho-p65 NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) (Cell Signaling Technology, USA), AKT, (IκBα) inhibitor of kappa B, insulin receptor (IR), Vinculin, and JNK (Santa Cruz Biotechnology, USA). Finally, the blots were developed with Clarity ECL Western Blot (BioRad). Values of scanning densitometry were determined using the Quantity One software (Bio-Rad, UK).

2.17. Lentiviral silencing of *Ptpn1* in Caco-2 cells {#sec2.17}
-----------------------------------------------------

A stable cell line of Caco2 silenced for *Ptpn1* gene, that encodes PTP1B protein, was generated by transduction with a battery of lentiviral particles TRCN0000218522, TRCN0000226109, TRCN0000226108, TRCN0000226107, and TRCN0000226106 (Mission shRNA Transduction Particles, Sigma Aldrich, USA) following the manufacturer\'s protocol. Lentiviral particles with Scramble shRNA were used as a control. Transduced cells were selected with puromycin (2.5 μg/mL) for 2 weeks. Transduction was confirmed by measuring *Ptpn1* expression by RT-qPCR. Stable cell-lines were obtained and referred as Caco-2 Scramble (Caco-2 sh*Scrb*) and Caco-2 sh*Ptpn1.*

2.18. Determination of TransEpithelial Electrical Resistance (TEER) {#sec2.18}
-------------------------------------------------------------------

For the analysis of TEER, Caco-2 cells (epithelial cells from human colon adenocarcinoma) were grown in (EMEM) Minimum Essential Medium - Eagle with Earle\'s BSS (Lonza, Switzerland) supplemented with 20% FBS and 1% P/S on porous filter membranes (0.4 μm-diameter pore) (Transwell® Permeable Support 0.4 μM Polyester Membrane Ref. 3460, Costar, Strasbourg, France). TEER was measured with a Millicell-ERS system (Millipore, USA) every 3 days until cells formed a monolayer. A monolayer was considered to be formed when three consecutive stable TEER measurements were obtained. Caco-2 cells were treated with mCM-C or mCM-LPS, and TEER was measured at the indicated time points.

2.19. Two-dimensional (2D) organoid culture and analysis of GLP-1 secretion {#sec2.19}
---------------------------------------------------------------------------

Transgenic mice (GLU-*Epac2camps*) bearing glucagon promoter-driven YFP expression that marks functional enteroendocrine (EEC) L cells were used. Colonic intestinal organoid lines were established using the procedure described previously \[[@bib35]\] and underwent a differentiation protocol, which involved withdrawal of Wnt3A 5--7 days before plating in a 2D culture. For plating 2D organoid cultures, differentiated organoids were collected in ice cold advanced DMEM:F12 (ADF) medium (Life Technologies, USA) and centrifuged at 200 × g for 5 min. The pellet was broken up enzymatically with TrypLE (Gibco, Thermofisher, USA) for 2 min at 37 °C and neutralized with ADF supplemented with 10% FBS and 10 μM ROCK inhibitor y27632 (Tocris, USA). Resulting single cells and clusters were centrifuged at 300 × g for 5 min, resuspended in organoid medium, and seeded onto 2% Matrigel-coated 48-well plates for GLP-1 secretion measurement \[[@bib36]\]. After overnight incubation (37 °C, 5% CO~2~), 2D cultures were washed three times in warm standard saline solution 138 buffer \[consisting of (in mM) NaCl (138), KCl (4.5), HEPES (10), NaHCO~3~ (4.2), NaH~2~PO~4~ (1.2), [d]{.smallcaps}-glucose (1), CaCl~2~ (2.6), MgCl~2~ (1.2); pH 7.4 with NaOH\] and 0.1% fatty acid-free BSA. Cells were incubated with pCM-C or pCM-LPS at 37 °C for 6 h. Supernatants were removed from the organoids and centrifuged at 2000 × g for 5 min at 4 °C, transferred to a fresh tube, and snap frozen on dry ice. Meanwhile, cells were lysed in 150 μL of lysis buffer on ice, and frozen overnight before lysates were scraped, collected, and centrifuged at 10,000 × g for 10 min at 4 °C. Samples were stored at −80 °C until measurement by the Core Biochemistry Assay Lab facility (Cambridge, UK). GLP-1 levels were measured using the total GLP-1 ELISA kit (MesoScale Diagnostics, USA) following the manufacturer\'s instructions \[[@bib36]\].

2.20. Colonic epithelial cultures and analysis of GLP-1 secretion {#sec2.20}
-----------------------------------------------------------------

Colonic crypts were isolated and cultured from 3- to 6-month-old C57BL/6 J mice of either sex as previously described \[[@bib37]\]. Mice were euthanized, and the colon was excised. Luminal contents were flushed with cold PBS, and the outer muscle layer was removed. Tissues were minced and digested with collagenase type XI (0.35 mg/mL). Crypt-containing fractions were centrifuged at 100 × g for 3 min and resuspended with DMEM supplemented with 10% FBS, 1% P/S, and 2 mM [l]{.smallcaps}-glutamine (Gibco, Life Technologies) before filtering through a 70-μm cell strainer. Colonic crypts were plated onto Matrigel (BD Bioscience) coated 48-well plates and placed overnight in a 5% CO~2~ incubator at 37 °C. For analysis of GLP-1 secretion, primary colonic epithelial cultures were seeded into 48-well plates as already described. After 1 day in culture, the culture medium was exchanged for fresh warmed medium with or without the PTP1B inhibitor (20 μM) or vehicle (DMSO) as a control. After incubation at 37 °C for 2 h, the culture medium was replaced by pCM-C or pCM-LPS for a further 6 h. An additional control group of culture medium was included (RPMI-2% FBS not exposed to macrophage cultures). The PTP1B inhibitor was kept during all the treatments. Supernatant and lysate samples were collected and processed for GLP-1 as previously indicated.

2.21. Statistical analysis {#sec2.21}
--------------------------

Statistical analysis was performed using GraphPad Prism v5. Sample outliers were found using the Grubbs test. The Shapiro--Wilk test was run to determine whether the samples showed a parametric or non-parametric distribution. Unpaired two-tailed Student\'s t-tests were used to do pairwise comparisons in parametric distributions, and the Mann--Whitney U test was used for non-parametric distributions. Two-way analysis of variance (ANOVA) with post-hoc Tukey test was employed to compare two different categorical independent variables (i.e., diet and genotype). When another statistical analysis different from the one described was used, it is indicated in the description of the corresponding result. The data are presented as the mean ± standard error of the mean (SEM). Differences were considered statistically significant when p \< 0.05.

3. Results {#sec3}
==========

3.1. Characterization of gut microbiota in PTP1B WT and PTP1B KO mice during NASH {#sec3.1}
---------------------------------------------------------------------------------

PTP1B WT and PTP1B KO mice were fed a chow or MCD diet for 4 weeks, and 16s rRNA microbiome analysis of feces was performed at the end of the treatment. α-diversity, determined by the Shannon index \[[@bib38]\], showed a trend to a decrease in mice from both genotypes fed a MCD diet; this effect was statistically significant only for PTP1B KO mice ([Figure 1](#fig1){ref-type="fig"}A). The analysis of β-diversity showed a marked difference between fecal microbiota of mice fed chow or MCD diets with a clear separation of both clusters of samples along the experimental protocol ([Figure 1](#fig1){ref-type="fig"}B). Furthermore, a separation in PTP1B WT and PTP1B KO clusters was appreciated particularly during NASH. Fecal profiling analyzed by unweighted UniFrac algorithm evidenced significant differences in microbiota composition between groups at different taxonomic levels ([Table 1](#tbl1){ref-type="table"}). As expected, the phyla *Firmicutes* and *Bacteroidetes* represent more than 80% of all bacterial species in mice fed a chow diet, and no differences between genotypes were found in the *Firmicutes*/*Bacteroidetes* (*F*/*B*) ratio ([Figure 1](#fig1){ref-type="fig"}C). However, in PTP1B WT mice under a MCD diet, the abundance of *Firmicutes* increased, whereas a marked decrease was observed in *Bacteroidetes*, leading to a higher *F*/*B* ratio. Of note, no changes in *F/B* ratio were found in MCD diet-fed PTP1B KO mice compared with their genotype counterparts fed a chow diet. Phylum TM7 abundance also exhibited a decrease in animals fed a MCD diet; these changes were statistically significant only for PTP1B KO mice ([Table 1](#tbl1){ref-type="table"}). At the family level, we found that *S24-7*, *Lactobacillaceae*, and *Mogibacteriaceae* families decreased similarly in both genotypes during NASH, whereas *Lachnospiraceae* and *Dehalobacteriaceae* decreased only in PTP1B WT mice. Moreover, families *Turicibacteriaceae* and *Verrucomicrobiaceae* appear to be decreased in PTP1B KO mice after 4 weeks on the MCD diet. Conversely, families *Porphyromonadaceae*, *Rikenellaceae*, and *Erysipelotrichaceae* were increased in both genotypes during NASH, whereas *Turicibacteriaceae* increased only in MCD diet-fed PTP1B WT mice. Finally, at the genus level, *Adlercreutzia*, *Lactobacillus*, *Roseburia*, and *Desulfovibrio* showed a decrease with NASH in both genotypes, whereas an increase in *Parabacteroides* and *Allobaculum* relative levels were observed. In this regard, only MCD diet-fed PTP1B KO mice exhibited an increase in *Prevotella* and a decrease in *Turicibacter*, whereas PTP1B WT mice showed an increase in *Turicibacter* genera during NASH ([Table 1](#tbl1){ref-type="table"}).Figure 1**Gut microbiota composition and functional changes.** A) Alpha-diversity analysis for PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks. Shannon index is expressed as mean ± SEM. ^\#\#\#^p \< 0.001 PTP1B KO chow *vs* PTP1B KO MCD. B) Phylogenetic β-diversity of fecal microbiota. Graph represents principal coordinate analysis (PCoA) plot based on 16 S rRNA gene sequencing of stool samples from PTP1B WT (blue symbols) and PTP1B KO (red symbols) mice fed a chow or MCD diet for 4 weeks. Differences between genotypes in this case are indicated with different clouds. Pink cloud corresponds to animals fed chow diet and green cloud surrounds animals fed a MCD diet. C) Ratio *Firmicutes*/*Bacteroidetes (F/B)* is expressed as mean ± SEM. ^∗^p \< 0.05 PTP1B WT chow *vs* PTP1B WT MCD. D-E) Predicted functional changes in gut microbiota analyzed by PICRUSt tool. Bar graphs show significant differences in KEGG pathways. MCD_1 M refers to animals fed a MCD diet for 4 weeks; Chow\_ refers to animals fed a chow diet. Significant differences are shown as p-value at the right panel. n = 5--7 mice per experimental group.Figure 1Table 1Changes in gut microbiota composition at different taxonomic levels during NASH in PTP1B WT and PTP1B KO mice.Table 1![](fx2.gif)[^2]

Biochemical function of the microbial community was determined using PICRUSt software, which allows prediction of the functional characteristics of the gut microbiota under the different experimental conditions. PICRUSt analysis showed that the genes related to metabolism of cofactors/vitamins and energy balance were significantly underrepresented in PTP1B WT mice fed a MCD diet compared with their corresponding controls fed a chow diet ([Figure 1](#fig1){ref-type="fig"}D), and these changes were not found in PTP1B KO mice. Moreover when we compared both genotypes in MCD diet-fed animals, we found that microbiota from PTP1B WT mice were significantly enriched in genes for secondary bile acid biosynthesis compared with PTP1B KO mice, whereas microbiota from PTP1B KO mice were enriched in genes related to propanoate metabolism compared PTP1B WT mice during NASH ([Figure 1](#fig1){ref-type="fig"}E).

3.2. Effect of PTP1B deficiency on serum bile acids during NASH {#sec3.2}
---------------------------------------------------------------

Bile acids are mediators in the cross-talk between the liver and gut and can modulate gut microbiota and also be modulated by the host gut microbiota \[[@bib39]\]. We quantified bile acids in serum to verify if their levels were altered in the context of PTP1B deficiency and/or MCD diet-induced NASH. Cholic (CA), chenodeoxycholic (CDCA), and ursodeoxycholic (UDCA) primary bile acids in mice were significantly augmented in serum of PTP1B WT mice receiving the MCD diet, but this increase did not reach significance in PTP1B KO mice as depicted in [Figure 2](#fig2){ref-type="fig"}A--C. Moreover, taurocholic (TCA) and taurochenodeoxycholic (TCDCA) acids, also primary bile acids resulting from the conjugation with taurine of CA and CDCA, respectively, exhibited higher levels in serum in the NASH condition, but no differences were found between genotypes ([Figure 2](#fig2){ref-type="fig"}D--E). We also found changes in CDCA-derived tauro α-muricholic acid (TαMCA), a primary bile acid in mice \[[@bib40]\]. As shown in [Figure 2](#fig2){ref-type="fig"}F, its serum levels were more elevated in PTP1B KO mice. In addition, the secondary bile acid taurodeoxycholic (TDCA) increased in MCD diet-induced NASH exclusively in PTP1B WT mice ([Figure 2](#fig2){ref-type="fig"}G). The analysis of *Nr1h4* mRNA, encoding the nuclear bile acid receptor farnesoid X receptor (FXR), in the gut showed higher levels in PTP1B KO mice under NASH ([Figure 2](#fig2){ref-type="fig"}H).Figure 2**Bile acid levels in serum samples from PTP1B WT and PTP1B KO mice fed chow or MCD diet.** A-G) Mean ± SEM of bile acids concentrations in serum samples are expressed as part per billion (ppb). n = 10--15 mice per experimental group. H) *Nr1h4* mRNA levels in the gut (encoding FXR protein). White dots represent mice fed a chow diet and black dots represent mice fed a MCD diet. n = 10--15 mice per experimental group. ∗p\< 0.05; ^∗∗^p \< 0.01; PTP1B WT chow *vs* PTP1B WT MCD; ^\#^p \< 0.05; ^\#\#^p \< 0.01 PTP1B KO chow *vs* PTP1B KO MCD; ^+^p \< 0.05; ^++^p \< 0.01 PTP1B WT MCD *vs* PTP1B KO MCD.Figure 2

3.3. Differential alterations in gut barrier permeability in PTP1B WT and PTP1B KO mice during NASH {#sec3.3}
---------------------------------------------------------------------------------------------------

We measured endotoxin levels in serum samples as an indicator of microbial product translocation, and higher circulating endotoxin levels were found in mice from both genotypes fed a MCD diet during 4 weeks compared with animals receiving a chow diet ([Figure 3](#fig3){ref-type="fig"}A). However, endotoxin levels were lower in MCD diet fed-PTP1B KO mice. Intestinal permeability was also analyzed by an *in vivo* FITC-dextran assay. [Figure 3](#fig3){ref-type="fig"}B shows that, in agreement with endotoxin levels, PTP1B WT mice showed a more pronounced increase in serum FITC-dextran levels after NASH induction, reflecting increased intestinal permeability compared with PTP1B KO mice. Better preservation of the gut barrier under NASH conditions in PTP1B KO mice was also confirmed by ZO-1 immunostaining ([Figure 3](#fig3){ref-type="fig"}C).Figure 3**Alterations in the gut barrier permeability in PTP1B WT and PTP1B KO mice during NASH.** A) LPS levels in serum after 4 weeks of feeding mice a chow or MCD diet. n = 6--9 mice per group. B) FITC-dextran assay in PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks. Data are expressed as percentage of FITC-dextran levels absorbed in serum samples. n = 9--16 animals per experimental group. ^∗∗∗^p \< 0.001 PTP1B WT chow *vs* PTP1B WT MCD; ^\#\#\#^p \< 0.001 PTP1B KO chow *vs* PTP1B KO MCD; ^++^p \< 0.01 PTP1B WT MCD diet *vs* PTP1B KO MCD diet. C) Representative images of ZO-1 immunostaining in colon samples of PTP1B WT and PTP KO mice. Scale bar 50 μm. D) Effect of the pro-inflammatory environment on TEER values in Caco-2 *shScrb* and Caco-2 *shPtpn1* monolayers. TEER values from Caco-2 *shScrb* or *shPtpn1* cultured in Transwell plates treated with mCM-C or mCM-LPS are represented as percentage of baseline. Data are expressed as mean ± SEM of three independent experiments performed in triplicate. ^∗∗∗^p \< 0.001 Caco-2 *shScb* mCM-LPS *vs* mCM-C; ^\#\#\#^p \< 0.001 Caco-2 *shPtpn1* mCM-LPS *vs* mCM-C.Figure 3

We used human Caco-2 colon cells infected with lentiviral particles encoding scrambled shRNA (sh*Scrb*) or *Ptpn1* shRNA (sh*Ptpn1*) to measure TEER, a common method for *in vitro* analysis of the barrier properties in epithelial intestinal cells \[[@bib41],[@bib42]\]. A comparison between the TEER values of Caco-2 sh*Scrb* and Caco-2 sh*Ptpn1* cell lines treated with mCM collected from Raw 264.7 macrophages without (mCM-C) or with (mCM-LPS) LPS stimulation as described in the Materials and Methods is shown in [Figure 3](#fig3){ref-type="fig"}D, and the raw data of TEER values are included in [Supplementary Table 1](#appsec1){ref-type="sec"}. After 24 and 48 h of treatment of Caco-2 sh*Scrb* or sh*Ptpn1* cell lines with mCM-LPS, TEER measurements decreased significantly to approximately half the levels detected in cells treated with mCM-C regardless of PTP1B expression. These results indicate that PTP1B deficiency does not directly impact on the barrier properties in the monolayer system of Caco-2 cells.

3.4. Colonic changes in PTP1B WT and PTP1B KO mice during NASH {#sec3.4}
--------------------------------------------------------------

Interestingly, under basal conditions (chow diet), colonic crypts were 51.6% ± 22.46% deeper in mice with deletion of the *Ptpn1* gene compared with PTP1B WT control mice (p \< 0.05). Colitis is usually associated with the presence of edema due to alterations in lymphatic vessel function triggered by the inflammatory mediators \[[@bib43], [@bib44], [@bib45]\]. Because MCD diet-induced NASH generates a pro-inflammatory environment \[[@bib46]\], we tested the presence of edema through the analysis of colon moisture content. [Figure 4](#fig4){ref-type="fig"}A shows an increase in colon water content of 3% and 4% in MCD diet-fed PTP1B WT and PTP1B KO animals, respectively, which reached significance only in PTP1B KO mice. However, when we determined the colon weight/length-to-body weight ratio, a parameter used to determine colon edema \[[@bib47],[@bib48]\], no differences were found between the four groups of animals ([Supplementary Fig. 1A](#appsec1){ref-type="sec"}), an effect probably due to the decrease of body mass associated with MCD administration. Therefore, it seems that this parameter does not determine colon edema in a pathological model such as MCD diet-induced NASH. Furthermore, we analyzed the bowel content searching for diarrhea, a symptom of advanced colitis. Surprisingly, MCD diet-fed animals exhibited lower number of fecal pellets and lower water content in colon feces ([Supplementary Figs. 1B--C](#appsec1){ref-type="sec"}).Figure 4**Analysis of anatomical and histological parameters in colon samples from PTP1B WT and PTP1B KO mice fed a chow or MCD diet for 4 weeks.** A) Colon moisture content is expressed as percentage of water regarding total colon weight. n = 7--8 mice per experimental group. B) Colonic epithelial granuloma areas expressed as percentage of total epithelium area. n = 4 mice per experimental group. C) Representative images of H&E colonic stained sections from PTP1B WT and PTP1B KO mice. Images were taken from 5 μm colon paraffin-embedded sections stained with H&E with an Axio Scan. Z1 (Zeiss). Granuloma areas are marked with a white symbol. D) Mucin layer analysis in colonic samples from mice under NASH conditions. Images show AB (left) (n = 8--16 crypts per experimental group) and PAS (right) stained representative crypts from colonic sections that stain acidic and neutral mucins, respectively (n = 17--24 crypts per experimental group). E) *Muc2* (mucin) mRNA levels are shown as fold change referred to the control PTP1B WT fed a chow diet. Data are expressed as mean ± SEM. n = 5--8 mice per experimental group. ^∗^p \< 0.05; ^∗∗^p \< 0.01 PTP1B WT chow *vs* PTP1B WT MCD; ^\#^p \< 0.05; ^\#\#\#^p \< 0.001 PTP1B KO chow *vs* PTP1B KO MCD.Figure 4

The histopathological analysis of colon samples did not show substantial changes in tissue epithelium such as hyperplasia or altered mucosa architecture. However, colonic mucosa from PTP1B KO mice contained unspecific granulomas not only after the challenge with MCD diet, but also before the induction of NASH ([Figure 4](#fig4){ref-type="fig"}B--C). Furthermore, PAS and AB staining was performed in colonic sections to evaluate colon mucosal integrity. [Figure 4](#fig4){ref-type="fig"}D shows decreased mucin levels in both genotypes of mice during NASH. Results for *Muc2* (the gene encoding for Mucin-2) mRNA levels in colon corroborated this decrease ([Figure 4](#fig4){ref-type="fig"}E).

Beyond epithelial and endocrine cells \[[@bib49]\], the intestine comprises a complex network of immune cells. Among them, a specialized gut immune cell population known as intraepithelial lymphocytes (IELs) modulates innate immunity and controls gut barrier function, epithelial turnover, and the host response to enteric pathogens \[[@bib13]\]. Based on that, we analyzed the expression of T-cell surface glycoprotein CD3γ (*Cd3g*) as the IEL marker in colon samples. As depicted in [Figure 5](#fig5){ref-type="fig"}A, PTP1B KO mice exhibited a greater than two-fold increase in *Cd3g* mRNA levels compared with PTP1B WT mice on a chow diet. Similar results were obtained when we evaluated the natural killer and cytotoxic T lymphocyte marker granzyme B (*Gzmb*) ([Figure 5](#fig5){ref-type="fig"}B). Likewise, the analysis of interferon gamma (*Ifng*) expression levels, a natural killer and CD4 Th1/CD8 cytotoxic T lymphocyte marker, showed an increase in PTP1B KO mice fed a MCD diet compared with PTP1B WT animals under the same conditions ([Figure 5](#fig5){ref-type="fig"}C). In light of these results, the expression levels of the inducible nitric oxide synthase (*Nos2*) were higher in PTP1B KO mice compared with PTP1B WT animals after NASH induction ([Figure 5](#fig5){ref-type="fig"}D). Taken together, these results along with the presence of edema ([Figure 4](#fig4){ref-type="fig"}A) and the mucosal inflammation noted in PTP1B KO mice, particularly during NASH ([Figure 4](#fig4){ref-type="fig"}B--C), shed light on an effect of PTP1B deficiency on constitutive colonic mucosal inflammation further exacerbated during MCD diet-induced NASH. Interestingly, *Ptpn1* levels were decreased in colon samples from PTP1B WT mice, reflecting an inverse relationship between this phosphatase and inflammation ([Figure 5](#fig5){ref-type="fig"}E). Conversely, the evaluation of mRNA levels of genes encoding pro-inflammatory cytokines \[interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and transforming growth factor beta (TFG-β)\] and fibroblast growth factor 7 (FGF7) in colon samples did not show significant differences among the experimental groups (data not shown).Figure 5**mRNA expression levels of pro-inflammatory markers in colon samples of PTP1B WT and PTP1B KO mice during NASH.** A-E) *Cd3g* (T-cell surface glycoprotein CD3 γ), *GzmB* (granzyme B), *Ifng* (interferon gamma), *Nos2* (inducible nitric oxide synthase), and *Ptp1n* (PTP1B) mRNA levels are shown as fold change referred to the control PTP1B WT fed a chow diet. White dots correspond to mice fed a chow diet and black dots to mice fed a MCD diet during 4 weeks. Data are expressed as mean ± SEM. n = 5--10 mice per experimental group. ^∗∗∗^p \< 0.001 PTP1B WT chow *vs* PTP1B WT MCD; ^\#\#^p \< 0.01 PTP1B KO chow *vs* PTP1B KO MCD; ^+^p \< 0.05; ^++^ p\< 0.01; ^+++^p \< 0.001 PTP1B WT MCD *vs* PTP1B KO MCD.Figure 5

3.5. Impact of PTP1B deficiency on GLP-1 secretion, EECs pro-inflammatory-mediated signaling, and expression of GLP-2 target genes {#sec3.5}
----------------------------------------------------------------------------------------------------------------------------------

It has been demonstrated that glucagon-like peptide-1 (GLP-1) binds to GLP-1R in IELs and suppresses the pro-inflammatory cytokine program, thereby protecting against gut inflammation \[[@bib13]\]. To assess the ability of a pro-inflammatory stimulus to induce GLP-1 secretion *in vivo*, we injected C57BL/6 J mice with a single dose of LPS (2 mg/kg), and plasma GLP-1 levels in response to an oral glucose challenge were analyzed 16 h later. As shown in [Figure 6](#fig6){ref-type="fig"}A, a three-fold increase in circulating GLP-1 was found in LPS-injected mice in agreement with previous studies \[[@bib12],[@bib13]\]. Since GLP-1 is secreted by EECs of the gut, we evaluated the impact of a pro-inflammatory environment in GLP-1 secretion in colonic organoid cultures generated from GLU-*Epac2camps* mice (see Materials and Methods). Organoids were stimulated with either regular medium (DMEM-2% FBS) or with CM collected from peritoneal macrophages stimulated with LPS (pCM-LPS) or left untreated (pCM-C) for 6 h. A significant increase in GLP-1 released to the medium was found in organoids cultured in pCM-LPS compared with those cultured in regular medium, indicating that a pro-inflammatory stimulus is able to trigger GLP-1 secretion both *in vivo* and *ex vivo* ([Figure 6](#fig6){ref-type="fig"}B).Figure 6**Effect of PTP1B deficiency on GLP-1 release by the gut under pro-inflammatory stimuli.** A) GLP-1 serum levels from C57BL/6 J mice injected with LPS (2 mg/kg body weight) as described in Materials and Methods. Black dots represent control animals and gray dots correspond to animals under an LPS acute pro-inflammatory stimulus. n = 4--7 mice per experimental group. ∗p\<0.05 PTP1B WT *vs* PTP1B WT LPS. B) Upper panel represents GLP-1 release from colonic organoids stimulated with pCM-LPS compared with organoids treated with pCM-C and DMEM-2%FBS. n = 2 independent experiments performed in triplicate. ^∗∗^ p\< 0.01 DMEM vs CM-LPS. Lower panel shows colonic organoids images used in this experiment. Upper panel shows a colonic organoid with budding crypt-like domains. Bottom panel shows an organoid with mature EEC L cells. Both images correspond to the same organoid, left image under light microscopy, right image under fluorescence microscopy. L cells (yellow fluorescence YFP) are shown in the right image. C) GLP-1 levels measured in the culture media from colonic crypts cultured under pro-inflammatory conditions. Data are expressed as fold change referred to control medium (DMEM alone). n = 3 independent experiments performed in quadruplicate. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 data referred to basal conditions; ^\#\#\#^p \< 0.001 referred to pCM-LPS. D) GLP-1 serum levels measured in animals under chow or MCD diet during 4 weeks. n = 5--7 mice per experimental group. ^∗∗∗^p \< 0.001 PTP1B WT chow *vs* PTP1B WT MCD; ^++^p \< 0.01 PTP1B WT chow *vs* PTP1B KO chow. E) *Gcg* mRNA levels (encoding proglucagon) are shown as fold difference referred to the control PTP1B WT fed a chow diet. White dots correspond to mice fed a chow diet and black dots to mice fed a MCD diet during 4 weeks. All data are expressed as mean ± SEM. n = 5--8 animals per experimental group. ^∗∗∗^p \< 0.001 PTP1B WT chow *vs* PTP1B WT MCD ; ^\#\#\#^p \< 0.001 PTP1B KO chow *vs* PTP1B KO MCD.Figure 6

Next, we analyzed the impact of chemical inhibition of PTP1B in GLP-1 secretion in primary cultures of colonic crypts under the aforementioned pro-inflammatory conditions. Treatment of primary colonic cultures with pCM-LPS increased GLP-1 secretion, an effect further enhanced by the presence of a PTP1B inhibitor ([Figure 6](#fig6){ref-type="fig"}C). Of note, GLP-1 secretion was also augmented when the PTP1B inhibitor was directly added to the primary cultures of colonic crypts. We extended these observations by evaluating GLP-1 levels in serum of PTP1B WT and PTP1B KO mice after a 4-hour fast and an oral glucose challenge as described in Materials and Methods and, as shown in [Figure 6](#fig6){ref-type="fig"}D, they were decreased in PTP1B WT mice fed a MCD diet compared with the levels found under a chow diet. Unexpectedly, PTP1B KO animals exhibited lower GLP-1 levels in serum under a chow diet, but these levels were preserved under NASH conditions. Of note, mRNA levels of *Gcg*, the precursor of GLP-1, were similarly downregulated in MCD diet-fed mice from both genotypes ([Figure 6](#fig6){ref-type="fig"}E), and no differences between genotypes were found in *Dpp4* expression in the colon (data not shown).

Since LPS or IL-6 has been shown to induce GLP-1 secretion by EECs \[[@bib12],[@bib50]\], we studied the impact of the mCM-LPS medium in the activation of pro-inflammatory signaling cascades in STC-1 cells. To achieve this, STC-1 cells were stimulated with mCM-LPS for short time periods. As depicted in [Figure 7](#fig7){ref-type="fig"}A, phosphorylation of JNK and p65 NFκB was markedly increased in STC-1 cells stimulated with mCM-LPS. Likewise, under these conditions, a more rapid degradation of IκBα was observed, likely reflecting an enhancement of NFκB pathway activation. Of note, these pro-inflammatory cascades in STC-1 cells were further enhanced by the presence of the PTP1B inhibitor in the mCM-LPS.Figure 7**Inflammatory and insulin signaling in enteroendocrine STC-1 cells stimulated with pro-inflammatory conditioned media.** A) STC-1 cells were pre-incubated or not for 2 h with the PTP1B inhibitor (20 μM) before the treatment with mCM-LPS for 5, 15, or 30 min. The dishes pretreated with the PTP1B inhibitor were used throughout the experiment. At the end of the culture time, cells were lysed and protein extracts were analyzed by western blot with the corresponding antibodies. Vinculin was used as a loading control. Right panel shows representative western blots. In the left panel, graphs show quantification of three independent experiments performed in duplicate. ^∗∗^p \< 0.01 mCM-LPS plus PTP1B inhibitor *vs* mCM-LPS. B) PTP1B inhibition protected against the drop of insulin signaling in EECs stimulated with pro-inflammatory conditioned medium. STC-1 cells were pre-incubated with the PTP1B inhibitor (20 μM) before the treatment with mCM-LPS or mCM-C for 16 h. Then, insulin was added for an additional 15 min. Protein extracts were prepared, and the phosphorylation of the IR and AKT was analyzed by western blot with the antibodies against phospho-IR, phospho-AKT Ser473, phospho-AKT Thr308, total IR, and total AKT. An anti-p85-PI3K antibody was used as a loading control. Right panel shows representative western blots. In the left panel, graphs show quantification of three independent experiments. The different experimental conditions are indicated under the blots or graphs. Data are shown as mean ± SEM. ^+^ p \< 0.05 mCM-LPS plus PTP1B inhibitor vs mCM-LPS.Figure 7

It has been reported that insulin via IR-mediated signaling stimulates proglucagon gene expression and, subsequently, the secretion of GLP-1 \[[@bib51],[@bib52]\]. Since PTP1B dephosphorylates and switches off IR tyrosine kinase activity, we analyzed the impact of PTP1B inhibition in insulin signaling in STC-1 cells. [Supplmentary Fig. 2A](#appsec1){ref-type="sec"} shows that the pre-treatment with a selective PTP1B inhibitor for 2 h before insulin stimulation further enhanced IR and AKT (Ser473 and Thr308 residues) phosphorylation. A step further, insulin signaling was decreased by the presence of the pro-inflammatory environment of the mCM-LPS ([Supplementary Fig. 2B](#appsec1){ref-type="sec"}) and, importantly, PTP1B inhibition increased insulin signaling even in these pro-inflammatory conditions ([Figure 7](#fig7){ref-type="fig"}B). Altogether, these results suggest that PTP1B plays a role in GLP-1 secreting EECs in the context of inflammation and IR-mediated signaling.

In addition to GLP-1, GLP-2 has also a beneficial effect on gut mucosal integrity as an intestinotrophic factor mainly by stimulating crypt cell proliferation, an effect mediated by the intestinal IGF-1-IGF-1R system \[[@bib53], [@bib54], [@bib55]\]. Because PTP1B deficiency enhances IGF-1R-mediated effects in a cell autonomous manner \[[@bib56]\], we hypothesized that constitutive enhancement of GLP-2 effects would contribute to the better preservation of the gut barrier integrity in PTP1B KO mice. As depicted in [Figure 8](#fig8){ref-type="fig"}A--C, constitutive expression levels of *Lyz* (encoding lysozyme) and *Kgf* (encoding keratinocyte growth factor), two GLP-2 responsive genes \[[@bib57]\], were significantly elevated in colon samples from PTP1B KO mice under basal conditions (chow diet) together with a trend toward elevation of *Vip* (encoding vasoactive intestinal peptide) mRNA compared with the expression levels of PTP1B WT mice.Figure 8**mRNA expression levels of GLP-2 responsive genes in colon samples of PTP1B WT and PTP1B KO mice under NASH conditions.** A-C) *Lyz* (lysozyme), *Kfg* (keratinocyte growth factor), and *Vip* (vasointestinal peptide) mRNA levels are shown as fold change referred to the control PTP1B WT fed a chow diet. White dots correspond to mice fed a chow diet, and black dots correspond to mice fed a MCD diet. Data are expressed as mean ± SEM. n = 4--8 animals per experimental group. ^+^p\< 0.05; ^++^p \< 0.01 PTP1B WT chow diet *vs* PTP1B KO chow diet.Figure 8

4. Discussion {#sec4}
=============

This work has been focused on the study of gut barrier alterations during NASH, a chronic liver disease characterized by a robust pro-inflammatory component, as well as in deciphering a previously unknown role of PTP1B in this process. Since PTP1B displays cellular-specific dual effects, on the one hand, promoting insulin resistance and susceptibility to cell death in non-immune cells such as hepatocytes \[[@bib20],[@bib58]\] and, on the other, inhibiting the pro-inflammatory responses in immune cells \[[@bib21], [@bib22], [@bib23], [@bib24],[@bib59]\], the research on the duality of actions of PTP1B in gut cells (immune and non-immune) during NASH-mediated inflammation is relevant. Overall, our results have showed that both diversity and gut microbial composition are different between mice with a healthy liver and mice with NASH. In addition, some NASH-mediated alterations in gut microbiota are different in PTP1B KO and PTP1B WT mice, as will be discussed following.

It is well known that microbiota diversity is essential to maintain the stability and efficiency of this dynamic micro ecosystem \[[@bib60]\]. Our results show that the α-diversity, measured by Shannon index, is lower during MCD diet-induced NASH. Furthermore, the unweighted UniFrac PCoA plot analysis reflects a clustering of the microbial populations from animals fed a MCD diet far away from that of the controls fed a chow diet, confirming that MCD diet-induced NASH alters intestinal microbial populations. Moreover, taxonomy analysis showed that the main changes between the four experimental groups (PTP1B WT chow, PTP1B WT MCD, PTP1B KO chow, and PTP1B KO MCD) are due to NASH as a disease.

In PTP1B WT mice under a MCD diet, the abundance of *Firmicutes* increased, whereas a marked decrease was observed in *Bacteroidetes* leading to a higher *F*/*B* ratio. By contrast, we did not find changes in MCD diet-fed PTP1B KO mice, either in *F/B* ratio or in *Bacteroidetes* and *Firmicutes* abundance. In this regard, it has been previously described that patients with NASH have a significantly lower proportion of *Bacteroidetes* compared with healthy controls or those with NAFLD \[[@bib61]\]; whereas, decreased *F/B* ratio was found in patients with inflammatory bowel disease \[[@bib62]\]. Moreover, patients with NASH under a probiotic-supplemented diet exhibit a higher level of *Bacteroidetes* in parallel to a decrease in intrahepatic triglyceride content \[[@bib8]\].

Our data also show an increase in the families *Porphyromonadaceae* (and the corresponding genus *Parabacteroides*), *Erysipelotrichaceae* (and the corresponding genus *Allobaculum*), and *Rikenellaceae* in mice receiving a MCD diet for 4 weeks. In addition, an increase in the abundance of family *Turicibacteraceae* (and the corresponding genus *Turicibacter*) was also observed, but only in PTP1B WT animals. These variations agree with observations from other studies in mice under a MCD diet or in patients with NASH \[[@bib28],[@bib63], [@bib64], [@bib65]\]. Families *Rikenellaceae* and *Turicibacteraceae* are known to be associated with inflammatory states \[[@bib28]\] and might contribute to gut inflammation in mice receiving a MCD diet. Conversely, a significant decrease of families *S24-7*, *Dehalobacteriaceae*, *Mogibacteriaceae*, *Lactobacillae*, *Lachnospiraceae*, and genera *Adlercreutzia*, *Lactobacillus*, *Roseburia*, and *Desulfovibrio* was found in mice with NASH. In particular, a low presence of *Dehalobacteriaceae* was detected only in PTP1B WT mice, and the same was observed for *Lachnospiraceae*; but, its genus *Roseburia* decreased in mice from both phenotypes. Of special interest is the decrease observed in MCD diet-fed mice of *Lactobacillus* and *Roseburia*, two beneficial organisms producing lactate and butyrate, respectively. Lactate-producing bacteria promote lactate-converting organisms, such as *Roseburia*, that produce butyrate favoring the abundance of *Lactobacilli*, thereby contributing to the maintenance of the anti-inflammatory effects of these microorganisms \[[@bib28],[@bib66],[@bib67]\]. The observed decrease in genus *Desulfovibrio* with the MCD diet should cause a lower production of H~2~S in the gut, a compound that has been related to regulation of epithelial mucus production and decrease of systemic inflammation \[[@bib65],[@bib68]\]. Likewise, a lower abundance of *Adlercreutzia* and *Dehalobacteriaceae* might be related to altered lipid and glucose metabolism. In this regard, *Adlercreutzia* is characterized by its ability to produce equol, which binds to the G-protein-coupled estrogen receptor (GPER) and improves glucose tolerance \[[@bib69]\]. Conversely, *Dehalobateriaceae* has been reported to decrease in situations of hepatic lipid accumulation induced by environmental chemicals \[[@bib70]\]. Notably, two marked alterations are observed only in PTP1B KO mice. First, at the phylum level, *TM7* relative levels decreased in these mice during NASH. Phylum *TM7* has been described as a potential immunomodulatory due to its ability to inhibit TNFα production in macrophages \[[@bib71],[@bib72]\] and, consequently, its decrease could be associated with the exacerbation of inflammation in NAFLD in PTP1B KO mice \[[@bib25]\]. Because PTP1B KO mice present a constitutive pro-inflammatory phenotype, it is possible to speculate that the lower presence of phylum *TM7* might play a role in their immune responses during NASH progression. Second, the LPS-producing genus *Prevotella* increases in PTP1B KO mice under a MCD diet. This finding is somehow unexpected, since PTP1B KO mice under a MCD diet show a lower level of circulating LPS than WT animals. It is worth noting that some changes in microbiota described in the MCD diet-induced NASH, such as decreased level of *Lactobacillus* and *Roseburia* and increased level of *Prevotella,* are similar to those reported in individuals with lean NASH \[[@bib73]\], many of them with malnutrition (choline deficiency) or genetic impairment of phosphatidylcholine synthesis \[[@bib74]\].

A step forward, the PICRUSt functional approach showed that a MCD diet shifts metabolic pathways of the microbial community toward a reduction in genes involved in metabolism of cofactors and vitamins and energy balance in PTP1B WT, but not in PTP1B KO mice, pointing to an impact of PTP1B deletion in the changes of bacterial metabolism under the NASH condition. Of relevance, when we compared both genotypes, gut microbiota from PTP1B WT mice fed a MCD diet overexpressed genes involved in the synthesis of secondary bile acids, whereas PTP1B KO mice exhibited an increase in genes linked to propionate metabolism. Since propionate (a short-chain fatty acid) is considered to be a health promoting microbial metabolite that possesses biological activity at the intestine and intestinal epithelium level \[[@bib75]\], these differences likely associate PTP1B WT mice with a more harmful microbiota compared with their counterparts lacking PTP1B.

There is a growing interest in revealing the function of bile acids during NASH and their possible role in the onset and progression of this disease. In agreement with the work of Puri and co-workers \[[@bib76]\], we found a marked increase in primary bile acids in plasma in mice with NASH. It is known that primary bile acid synthesis is modulated by gut microbiota through the regulation of key enzymes of this metabolic pathway such as CYP7A1. Related to this, ileal FXR activation by its agonist CDCA leads to CYP7A1 inhibition \[[@bib77]\] and, therefore, decreases bile acid synthesis. During NASH, CA levels are much higher than CDCA levels and, as a result, FXR activation by CDCA is reduced, thereby increasing bile acid synthesis. Thus, the lower levels of CA found in serum from PTP1B KO mice during NASH point to a lower bile acid synthesis, which was manifested by decreased amounts of CA, CDCA, and UDCA. These data are reinforced by increased expression of the *Nr1h4* gene (coding FXR protein) observed in the gut of MCD diet-fed PTP1B KO mice compared with their PTP1B WT counterparts. In addition, as we remarked previously, PICRUSt predicted that gut microbiome from PTP1B WT mice fed a MCD diet is enriched in genes for secondary bile acid biosynthesis compared with PTP1B KO mice, and this could be the reason of the lower plasma levels of TDCA during NASH found in mice lacking PTP1B.

Although a number of studies have addressed the molecular mechanisms involved in the progression of NAFLD toward NASH, little is known about how the intestine is affected by this inflammatory disease. A recent study \[[@bib28]\] has reported the beneficial effect of butyrate on MCD diet-induced gut barrier dysfunction and inflammation in the liver. A previous clinical study \[[@bib78]\] demonstrated that both intestinal permeability and alterations in gut microbiota were increased in patients with NAFLD. In the present study, we found that colonic edema and, thus, colonic inflammation, was significantly enhanced only in PTP1B KO mice with NASH, suggesting exacerbated pro-inflammatory responses in this genotype as we previously reported \[[@bib24]\]. Moreover, the presence of inflammatory infiltrates in the colonic mucosa together with a marked increase in the expression levels of inflammatory markers such as *Ifng* and *Nos2* were found in PTP1B KO animals fed a MCD diet compared with PTP1B WT mice. Of note, PTP1B KO mice fed a chow diet showed increased expression levels of *Cd3g* and *GzmB* compared with PTP1B WT mice, reinforcing the fact that PTP1B KO mice exhibit an intrinsic pro-inflammatory susceptibility, which is exacerbated after NASH induction. Taking into account that PTP1B is a negative modulator of key immune signaling cascades \[[@bib24]\], our results suggesting that PTP1B deficiency likely facilitates the activation of macrophages (through increasing *Nos2*) and T lymphocytes (through *Ifng*, *Cd3g* and *GzmB*) in the gut are in line with data previously reported by our laboratory and others in different inflammatory contexts \[[@bib24],[@bib79]\]. Because NASH concurs with a systemic pro-inflammatory environment \[[@bib80]\], the enhancement of gut inflammation in PTP1B KO mice is somehow expected due to the dynamic cross-talk in the gut-to-liver axis.

To obtain further insights on differential gut barrier disruption in PTP1B WT and PTP1B KO mice with NASH, we measured their intestinal permeability by a FITC-dextran assay, which showed major flux of this fluorescent compound and, thus, major leakage in PTP1B WT mice. Similar results were obtained by the analysis of serum endotoxin content, confirming a disruption in the gut barrier function by the MCD diet and, importantly, a partial protection in PTP1B KO mice. We also explored gut barrier permeability in a cellular autonomous manner and found decreased TEER values in Caco-2 cells and, thus, disrupted barrier integrity under pro-inflammatory culture conditions in agreement with the work of Moran and co-workers showing decreased TEER in Caco-2 cells cultured with TNFα \[[@bib81]\]. However, no differences were observed between Caco-2 cells with silenced *Ptpn1* and the controls (sh*Scrb*). Taking into account that TEER measurement allows the study of barrier integrity in an epithelial monolayer depending only on the unions between cells \[[@bib42]\], these results suggest that specific PTP1B deficiency in the epithelial cells of the gut might not affect permeability in a relevant way. By contrast, the analysis of the tight junction protein ZO-1 in colon sections showed a better preservation of the gut barrier features in PTP1B KO mice fed a MCD diet. Thus, the results of the *in vivo* NASH model in which PTP1B deficiency confers protection against gut barrier disruption triggered by pro-inflammatory stimuli strongly suggest that environmental factors such as the aforementioned gut microbiota diversity rather than the gut epithelial cells may have a major contribution in maintaining the gut barrier integrity under this pathologic condition.

Recent findings have expanded the classical concept of enteroendocrine L cell biology toward sensors of inflammatory stimuli and compromised mucosal integrity, thereby linking GLP-1 secretion to gut inflammation. Yusta and co-workers showed that binding of GLP-1 to its receptor in IELs switches the pattern of the inflammatory response \[[@bib13]\]. In a recent study, Lebrun and co-workers \[[@bib12]\] reported increases in GLP-1 levels in circulation by LPS administration as well as in a dextran sulfate sodium- and ischemia/reperfusion-induced colitis model in mice, this effect being dependent on TLR4. A step further, the same study showed elevations in GLP-1 in human healthy volunteers receiving a single injection of LPS and patients subjected to ischemia/reperfusion in a jejunal segment during a pancreaticoduodenectomy. Moreover, Keller and co-workers \[[@bib82]\] showed increased release of GLP-1 in patients with inflammatory bowel disease. Despite the effects of acute pro-inflammatory stimuli or severe gut inflammation in triggering GLP-1 release to the circulation, our results showed that under a mild chronic pro-inflammatory environment (i.e. MCD diet), PTP1B WT animals had reduced circulating GLP-1 levels in response to an oral glucose challenge. A possible explanation for such effect could be supported by the existence of a cross-talk between EECs and IELs aimed to counteract elevated inflammation, although MCD diet-fed PTP1B WT mice might not have reached enough inflammatory thresholds to activate this compensatory mechanism through time. In line with these data, a human study reported reduced peak (15 min) GLP-1 concentrations in a cohort of 52 non-diabetic patients with NAFLD (including simple steatosis and NASH) compared with controls, as well as total GLP-1 secretion in an oral glucose tolerance test \[[@bib83]\]. Interestingly, PTP1B KO mice that already showed lower glucose-triggered GLP-1 responses on a chow diet were protected against the decrease of this incretin under a MCD diet. We speculate that the reduced GLP-1 responses found in PTP1B KO animals on a chow diet would prevent excessive postprandial insulin excursions in these systemic hypoinsulinemic and insulin-hypersensitive animals \[[@bib19],[@bib84]\] to avoid excessive hypoglycemia. Future research could unravel differences in the amount of IELs between PTP1B WT and PTP1B KO mice.

To further investigate the role of PTP1B in GLP-1 release by the gut under pro-inflammatory conditions as previously reported \[[@bib12],[@bib13]\], we performed *in vitro* studies in EECs, colonic organoids, and primary cultures of colonic crypts. Our results showed for the first time on the one hand, an effect of PTP1B inhibition by enhancing the pro-inflammatory signaling cascades triggered by the mCM-LPS (JNK, NFκB) in STC-1 cells, reinforcing our experimental evidence on the impact of this phosphatase in the interplay between immune (likely IELs) and EECs in the gut and, on the other, an unknown role of this phosphatase as a negative modulator of insulin signaling (IR, Akt) in EECs cells under basal or pro-inflammatory conditions. A step further, in a more physiological model using primary cultures of colonic crypts, we found a significant increase in GLP-1 release on treatment with the pro-inflammatory media and, more importantly, this effect was further increased in the presence of the PTP1B inhibitor that, as previously mentioned, increased the pro-inflammatory signaling cascades in EECs. Altogether, these results led us to suggest that PTP1B deficiency might affect both IELs and EECs by enhancing pro-inflammatory and insulin signaling, respectively, thereby boosting GLP-1 secretion. However, a limitation of the present study is the use of global PTP1B-deficient mice and, in this regard, future research will be needed to characterize the outcome of deficiency of this phosphatase in different gut cell types.

The results of the present study are apparently contradictory with our previous data \[[@bib25]\] showing accelerated NASH in PTP1B KO mice on a MCD diet due to enhanced immune responses in the liver. The protective mechanism in the intestine reported here seems to be tissue-specific and could be explained by the maintenance of GLP-1 levels in MCD diet-fed PTP1B KO mice that elicit an anti-inflammatory protective effect targeting IELs (as proposed by Yusta and co-workers \[[@bib13]\]) and probably other gut cell types, thereby preserving gut barrier permeability. In contrast, the severe hepatic phenotype of PTP1B KO mice on a MCD diet reported in our previous manuscript \[[@bib25]\] likely reflects a profound inflammation within the liver beyond endotoxemia that results from the enhancement of pro-inflammatory signaling cascades in immune cells of the liver, either resident or recruited, on NASH insult.

GLP-1 and GLP-2 are simultaneously produced via posttranslational processing of proglucagon by prohormone convertase 1/3 and co-secreted from intestinal L cells \[[@bib85]\]. In the context of gut inflammation, Lebrun and co-workers showed increases in plasma GLP-2 in mice receiving an acute injection of LPS or subjected to intestinal ischemia/reperfusion \[[@bib12]\]. In this regard, we found higher constitutive expression of GLP-2 sensitive genes in colon samples from PTP1B KO mice. These data are relevant since gut epithelial IGF-1R signaling has been shown to mediate the effects of GLP-2 in the proliferation of the gut crypts \[[@bib55]\], and it is plausible that PTP1B-deficiency might confer increased GLP-2 secretion together with IGF-1R-mediated sensitivity in the gut as occurs in pancreatic beta cells \[[@bib56],[@bib86]\], as demonstrated by the greater depth of the colonic crypts in PTP1B KO mice, thereby favoring gut mucosal integrity. Another possible explanation for the better preservation of the gut barrier in PTP1B KO mice is based on the requirement of insulin for the maintenance of normal rates of protein synthesis in the mucosa of the small intestine, an essential component of the remodeling process during damage \[[@bib87]\]. Thus, the decrease in the synthesis rate of small intestine mucosa under hypoinsulinemia in MCD-induced NASH might be attenuated in PTP1B KO mice due to their hypersensitivity to insulin.

5. Conclusions {#sec5}
==============

Taking all the results together, this study has identified a protective role of PTP1B deficiency against the shift in gut microbiome during NASH that was accompanied with less gut barrier permeability, preserved GLP-1 levels under a pro-inflammatory environment, and a potential sensitivity to GLP-2. Further investigation is required to identify the accurate mechanisms responsible for the ameliorated phenotype of PTP1B KO mice in the gut during this liver pathology with a possible therapeutic value.
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Appendix A. Supplementary data {#appsec1}
==============================

The following are the Supplementary data to this article:Supplementary Figure 1**Gut characterization in PTP1B WT and PTP1B KO mice under NASH conditions. A)** Graph represents the ratio colon weight/length for body weight. White and black bars represent animals fed a chow or MCD diet, respectively. n= 5-7 mice per experimental group. **B)** Upper panel shows quantification of number of feces in the colon from the four experimental animal groups. Lower panel shows representative images of colon samples. n= 4-8 mice per experimental group. **C)** Feces humidity was measured with the moisture analyzer MB120 (Ohaus). Percentage of humidity was calculated from the difference between final dried feces and starting fresh feces. Data are expressed as mean ± SEM. n=6-11 mice per experimental group. ∗p\<0.05; ∗∗p\<0.01 PTP1B WT chow *vs* PTP1B WT MCD diet; ^\#\#^p\<0.01; ^\#\#\#^p\<0. 001 PTP1B KO chow *vs* PTP1B KO MCD.Supplementary Figure 1Supplementary Figure 2**Effect of PTP1B inhibition in insulin signaling in EECs under proinflammatory stimulus. A)** STC-1 cells were pretreated or not for 2 h with the PTP1B inhibitor (20 μM) and then stimulated with insulin for 15 min. Protein extracts were prepared, and the phosphorylation of the IR and AKT was analyzed by western blot with the antibodies against phosho-IR, phospho-AKT Ser473, phospho-AKT Thr308, total IR, and total AKT. An anti-p85-PI3K antibody was used as a loading control. Left panel shows representative western blots. In the right panel, graphs show quantification of three independent experiments. Data are shown as mean ± SEM. n=3 independent experiments. ∗p\<0.05; ∗∗∗p\<0.001 DMEM alone *vs* insulin; ^++^p\<0.01; ^+++^p\<0.001 insulin plus PTP1B inhibitor *vs* insulin. **B)** STC-1 cells were pre-incubated with the PTP1B inhibitor (20 μM) before the treatment with mCM-LPS or mCM-C for 16 h. Then, insulin was added for a further 15 min. Protein extracts were prepared and the phosphorylation of the IR and AKT was analyzed by western blot with the antibodies against phosho-IR, phospho-AKT Ser473, phospho-AKT Thr308, total IR, and total AKT. An anti-p85-PI3K antibody was used as a loading control. Left panel shows representative western blots. In the right panel, graphs show quantification of three independent experiments. Data are shown as mean ± SEM. ^+++^p\<0.001 mCM-LPS vs mCM-C.Supplementary Figure 2Supplementary Table 1**TEER values of Caco-2 shScrb and Caco-2 shPtp1n cells under mCM-C or mCM-LPS treatment.** Two stable cell lines, Caco-2 scramble (Caco-2 shScb) and Caco-2 siPtpn1 (Caco-2 silenced for Ptpn1 gene, encoding for PTP1B protein), were cultured with mCM-C or mCM-LPS. TEER values were measured after 24 and 48 h. Data are expressed as mean values ± SEM. n=3 independent experiments performed in triplicate.Supplementary Table 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.molmet.2020.01.018>.
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[^2]: ^1^Comparison between the different conditions. Two-way ANOVA with a Tukey post-hoc test was performed for statistical analysis. ^a^Changes in gut microbiota due to the administered diet. ↑ expresses higher abundance and ↓ indicates lower abundance after 4 weeks of MCD diet relative to chow diet. ^b^Changes in gut microbiota due to the genotype. ↑ indicates higher and ↓ indicates lower abundance in PTP1B KO mice *vs* PTP1B WT mice. Taxa with differences due to diet and genotype are shown highlighted in purple. w refers to significant differences found only for PTP1B WT animals; k refers to significant differences found only for PTP1B KO animals. m refers to significant differences found only in MCD-fed animals. ^∗^p\<0.05; ^∗∗^p\<0,01; ^∗∗∗^p\<0.001. n=5-7 animals per condition.
